A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

Recruiting

Phase 3

DeucravacitinibA Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

Sponsor:

Bristol-Myers Squibb

Code:

NCT04772079

Conditions

Plaque Psoriasis

Eligibility Criteria

Sex: All

Age: 4 - 18

Healthy Volunteers: Not accepted

Interventions

Deucravacitinib

Placebo matching deucravacitinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-04. This information was provided to ClinicalTrials.gov by Bristol-Myers Squibb on 2025-09-25.